The roles of insulin‐like growth factor 2 mRNA‐binding protein 2 in cancer and cancer stem cells
J Cao, Q Mu, H Huang - Stem cells international, 2018 - Wiley Online Library
RNA‐binding proteins (RBPs) mediate the localization, stability, and translation of the target
transcripts and fine‐tune the physiological functions of the proteins encoded. The insulin …
transcripts and fine‐tune the physiological functions of the proteins encoded. The insulin …
Upregulation of insulin-like growth factor II mRNA-binding protein 3 (IMP3) has negative prognostic impact on early invasive (pT1) adenocarcinoma of the esophagus
Purpose Therapeutic decisions in esophageal adenocarcinomas (EAC) restricted to mucosa
(pT1a) or submucosa (pT1b) depend mainly on classic histomorphology-based criteria like …
(pT1a) or submucosa (pT1b) depend mainly on classic histomorphology-based criteria like …
The expression level of vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and insulin-like growth factor II mRNA binding …
O Eronat, O Kandemir, A Onursever - Clinical Cancer Investigation …, 2018 - ccij-online.org
Background: The malignant tumors of the kidney are the most aggressive among urologic
cancers. To treat patients with renal cell carcinoma (RCC), it is important to understand the …
cancers. To treat patients with renal cell carcinoma (RCC), it is important to understand the …
IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes
A Del Gobbo, A Morotti, AE Colombo, V Vaira, G Ercoli… - Medical Oncology, 2018 - Springer
Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy
is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied …
is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied …
Method for detection of L523S expression in biological samples
KM Sojka, EO Spaulding - US Patent 9,869,678, 2018 - Google Patents
The present invention discloses methods for differentiating between normal or reactive cells
and malignant cells in biological samples comprising: exposing the biological sample to an …
and malignant cells in biological samples comprising: exposing the biological sample to an …